A study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference showed that the PET radiotracer 18F-PSMA-1007 can improve the detection of metastatic lesions in prostate cancer. The study found that the radiotracer was associated with a 72% positivity rate for abnormal findings in a cohort of 160 patients, with a 74% positivity rate at initial staging and a 71% positivity rate for patients with biochemical recurrence. The radiotracer detected lymph node metastasis in 32% of patients and bone metastasis in 23% of patients. Therapy planning was modified in 42% of patients based on the results. The radiotracer also had a 51% detection rate for prostate tumor activity and a 46% detection rate for extra-prostate metastases, even in patients with low prostate-specific antigen levels.
Thu, 03 Aug 2023 23:47:49 GMT | Diagnostic Imaging